Aptus Capital Advisors LLC Purchases 34,831 Shares of Johnson & Johnson $JNJ

Key Points

• Aptus Capital Advisors increased its Johnson & Johnson stake by 21.2% in the fourth quarter, adding 34,831 shares and bringing its total holding to 199,225 shares worth about $41.23 million.
• Johnson & Johnson reported solid quarterly results, with EPS of $2.70 topping estimates and revenue of $24.06 billion beating forecasts; the company also reaffirmed FY 2026 EPS guidance of 11.45 to 11.65.
• The company raised its dividend to $1.34 per share quarterly from $1.30, lifting the annualized payout to $5.36 and implying a 2.2% yield, while analysts maintain a “Moderate Buy” consensus with an average price target of $253.04.

Aptus Capital Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 199,225 shares of the company's stock after acquiring an additional 34,831 shares during the quarter. Aptus Capital Advisors LLC's holdings in Johnson & Johnson were worth $41,230,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Blueline Advisors LLC bought a new position in Johnson & Johnson in the fourth quarter valued at $25,000. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter valued at $26,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson in the fourth quarter valued at $26,000. DecisionPoint Financial LLC increased its stake in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock valued at $30,000 after acquiring an additional 75 shares during the last quarter. Finally, Family CFO Inc bought a new position in Johnson & Johnson in the fourth quarter valued at $31,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.9%

Shares of NYSE:JNJ opened at $240.57 on Friday. The stock's 50-day moving average price is $231.51 and its 200-day moving average price is $227.20. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The stock has a market capitalization of $579.10 billion, a P/E ratio of 27.81, a price-to-earnings-growth ratio of 2.36 and a beta of 0.26. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. During the same period last year, the firm earned $2.77 earnings per share. The company's revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 61.97%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson agreed to pay about $1 billion for Firefly Bio technology, a bet on improving treatment options for one of cancer’s most hard-to-target areas. Article Title
• Positive Sentiment: J&J also reported encouraging late-stage results for IMAAVY in warm autoimmune hemolytic anemia, reinforcing the company’s pipeline momentum in rare diseases. Article Title
• Positive Sentiment: Analysts and commentators highlighted J&J as a defensive healthcare name with attractive valuation and dividend appeal, which can support buying interest in a volatile market. Article Title
• Neutral Sentiment: Jim Cramer mentioned J&J while favoring healthcare over technology, which is a sentiment tailwind but not a direct company-specific catalyst. Article Title
• Neutral Sentiment: Johnson & Johnson expanded U.S. availability of its TECNIS PureSee cataract lens, a positive commercial update but likely a smaller stock mover than the acquisition and pipeline news. Article Title
• Negative Sentiment: Ongoing talc-related legal headlines remain an overhang and could limit upside if investors focus back on litigation risk. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JNJ shares. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, April 15th. Weiss Ratings cut Johnson & Johnson from a "buy (b+)" rating to a "buy (b)" rating in a research note on Friday, April 24th. Johnson Rice raised Johnson & Johnson from a "hold" rating to an "outperform" rating in a research note on Wednesday, May 13th. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the company a "market perform" rating in a research note on Wednesday, April 15th. Finally, Citigroup raised their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, April 7th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $253.04.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.